132 related articles for article (PubMed ID: 32154740)
1. A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol.
Pouls BPH; Kristensen LE; Petersson M; van den Bemt BJF; Ballerini L; Bruggraber R; Karlen H; Mountian I; van Bracht E; Wiegratz S; Jørgensen TS
Expert Opin Drug Deliv; 2020 May; 17(5):705-711. PubMed ID: 32154740
[No Abstract] [Full Text] [Related]
2. A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol.
Tatla D; Mountian I; Szegvari B; VanLunen B; Schiff M
Expert Opin Drug Deliv; 2020 Jun; 17(6):855-862. PubMed ID: 32239971
[TBL] [Abstract][Full Text] [Related]
3. Six months multicentre pilot open label single-arm study to evaluate patient experience, acceptability and satisfaction of switching certolizumab pegol from a prefilled syringe or autoinjection pen to an AVA® e-Device in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis patients.
Borrás-Blasco J; Vicente-Escrig E; Rodríguez-Lucena FJ; García-Monsalve A; Arroyo-Domingo E; Ferrando-Piqueres R; Casterá E; Navarro-Ruiz A
J Clin Pharm Ther; 2022 Dec; 47(12):2345-2349. PubMed ID: 36470844
[TBL] [Abstract][Full Text] [Related]
4. Patient Satisfaction with CIMZIA
Bailey K; Mountian I; Bruggraber R; Sunderland K; Tilt N; Szegvari B
Adv Ther; 2020 Apr; 37(4):1522-1535. PubMed ID: 32124272
[TBL] [Abstract][Full Text] [Related]
5. Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies.
Domańska B; Stumpp O; Poon S; Oray S; Mountian I; Pichon C
Adv Ther; 2018 Jan; 35(1):100-115. PubMed ID: 29222625
[TBL] [Abstract][Full Text] [Related]
6. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Domańska B; VanLunen B; Peterson L; Mountian I; Schiff M
Expert Opin Drug Deliv; 2017 Jan; 14(1):15-22. PubMed ID: 27801596
[TBL] [Abstract][Full Text] [Related]
7. Usability of the Certolizumab Pegol Auto-Injection Device in Australian Patients with Chronic Rheumatic Diseases: Results from a Market Research Study.
Aw J; Griffiths H; Zochling J; Lanzafame A; Jordan A
Patient Prefer Adherence; 2021; 15():1469-1476. PubMed ID: 34234420
[TBL] [Abstract][Full Text] [Related]
8. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
[TBL] [Abstract][Full Text] [Related]
9. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ).
Keininger D; Coteur G
Health Qual Life Outcomes; 2011 Jan; 9():2. PubMed ID: 21232106
[TBL] [Abstract][Full Text] [Related]
10. Development and psychometric evaluation of the assessment of self-injection questionnaire: an adaptation of the self-injection assessment questionnaire.
Pompilus F; Ciesluk A; Strzok S; Ciaravino V; Harris K; Szegvari B; Mountian I; Cleanthous S; Meunier J
Health Qual Life Outcomes; 2020 Nov; 18(1):355. PubMed ID: 33148261
[TBL] [Abstract][Full Text] [Related]
11. The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases.
Jørgensen TS; Skougaard M; Taylor PC; Asmussen HC; Lee A; Klokker L; Svejstrup L; Mountian I; Gudbergsen H; Kristensen LE
Patient; 2018 Oct; 11(5):515-526. PubMed ID: 29948962
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
[No Abstract] [Full Text] [Related]
13. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
14. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.
Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Kobayashi M; Shoji T; Togo O; Miyasaka N; Koike T
Mod Rheumatol; 2016 Jul; 26(4):473-80. PubMed ID: 26472043
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
19. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
